SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 3, 2019
NGM Biopharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
333 Oyster Point Boulevard
South San Francisco, California
|(Address of Principal Executive Offices)||(Zip Code)|
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Name of each exchange
on which registered
|Common Stock, par value $0.001 per share||NGM||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.02|| |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 3, 2019 (the Effective Date), the Board of Directors (the Board) of NGM Biopharmaceuticals, Inc. (the Company) increased the authorized size of the Board from nine to ten members, creating a vacancy on the Board.
On the Effective Date, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Shelly Guyer to fill the vacant Board seat and to serve as a member of the Board with an initial term expiring at the Companys 2020 annual meeting of stockholders. In addition, the Board appointed Ms. Guyer to the Audit Committee of the Board.
There are no arrangements or understandings between Ms. Guyer and any other persons pursuant to which she was selected as a director of the Company. The Board has determined that Ms. Guyer is independent under the Companys Corporate Governance Guidelines, applicable U.S. Securities and Exchange Commission requirements and Nasdaq listing standards. There is no transaction involving Ms. Guyer that requires disclosure under Item 404(a) of Regulation S-K.
As of the Effective Date, Ms. Guyer will participate in the Companys Non-Employee Director Compensation Policy (the Policy). Under the Policy, Ms. Guyer will receive an annual retainer of $40,000 for her service on the Board, plus an additional $10,000 annual retainer for her services as a member of the Audit Committee, in each case starting on the Effective Date, with payment pro-rated for any partial period of service. In addition, on the Effective Date, Ms. Guyer received an option to purchase 48,355 shares of the Companys Common Stock, which will vest on an annual basis over three years, subject to Ms. Guyers continuous service as a member of the Board. The Company also entered into its standard form of indemnification agreement with Ms. Guyer.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|NGM Biopharmaceuticals, Inc.|
Dated: December 5, 2019
Senior Vice President and General Counsel